Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 17/20 | 0.68 |
| ▸ | CDK8 | P49336 | 17/20 | 0.68 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.55 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18491821 | 1.00 | CCNC (0.68) | CCNCCDK8CDK19SLC22A12MKNK1 | |
| SCHEMBL18491330 | 0.88 | CCNC (0.73) | CCNCCDK8CDK19SLC22A12 | |
| SCHEMBL18491331 | 0.88 | CCNC (0.73) | CCNCCDK8CDK19SLC22A12 | |
| SCHEMBL18492282 | 0.83 | CCNC (0.57) | CCNCCDK8CDK19 | |
| SCHEMBL18492284 | 0.83 | CCNC (0.57) | CCNCCDK8CDK19 | |
| SCHEMBL18491960 | 0.82 | CCNC (0.77) | CCNCCDK8CDK19MKNK1MKNK2 | |
| SCHEMBL18491962 | 0.82 | CCNC (0.77) | CCNCCDK8CDK19MKNK1MKNK2 | |
| SCHEMBL18492237 | 0.81 | CCNC (1.00) | CCNCCDK8CDK19 | |
| SCHEMBL18492239 | 0.81 | CCNC (1.00) | CCNCCDK8CDK19 | |
| SCHEMBL18492433 | 0.80 | CCNC (0.82) | CCNCCDK8CDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3205645-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-9957251-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| EP-3205645-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-16 | — | — | EP | disclosed |
| US-20170044132-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044132-A1 | HETEROCYCLIC COMPOUND | CDK19, CDK9, CDK8 | CCNC 28/4885CDK8 3/4885CDK19 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.